Axitinib

Licensed by Pfizer Catalog No.S1005 Synonyms: AG 013736

Axitinib Chemical Structure

Molecular Weight(MW): 386.47

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 32 Publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).
Targets
VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)
PDGFRβ [1]
(Porcine aorta endothelial cells)
0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM 1.6 nM
In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\KTWM2OD1yLkCwNFA2OTNizszN NGLXbJZUSU6JRWK=
NCI-H1703 NYXJb2I6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHre3FKSzVyPUCuNFAxQTB{IN88US=> M4DDe3NCVkeHUh?=
KASUMI-1 NVHPc3ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwMEC2PFIh|ryP M3nmcHNCVkeHUh?=
CGTH-W-1 NULLe4ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMEC3NlIh|ryP NEe5fVhUSU6JRWK=
A204 NV\CdnA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwMEC5PVIh|ryP M3zuWXNCVkeHUh?=
HOP-62 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHoWY5IUUN3ME2wMlExQDN4IN88US=> NHn3fIVUSU6JRWK=
H-EMC-SS Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vHZ2lEPTB;MD6xNVAxPSEQvF2= NF7EOmFUSU6JRWK=
KU812 NEHaSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWW0SIdJUUN3ME2wMlE3PTd5IN88US=> NH[xUYFUSU6JRWK=
EM-2 Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojtTWM2OD1yLkG2PFE3KM7:TR?= NIe0NWlUSU6JRWK=
LAMA-84 M1SxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofYTWM2OD1yLkG3OlY2KM7:TR?= MWjTRW5ITVJ?
JAR MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PKV2lEPTB;MD6yN|k5QSEQvF2= MU\TRW5ITVJ?
G-361 M2nLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwM{KzNlUh|ryP NUPXcYEyW0GQR1XS
KG-1 NU\YR2hUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzH[o5uUUN3ME2wMlM4PjR{IN88US=> NXLJRWFnW0GQR1XS
BV-173 M4nsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwM{mzNkDPxE1? MYDTRW5ITVJ?
K5 NH3RPJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDOZ2dKSzVyPUCuOFIyOjdizszN M3f6XnNCVkeHUh?=
MEG-01 MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPmTWM2OD1yLkSyN|YyKM7:TR?= NYSzdYJTW0GQR1XS
MFM-223 M2TpPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\oTWM2OD1yLkS0O|c3KM7:TR?= MnHPV2FPT0WU
BE-13 NULrfY1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT6NWhrUUN3ME2wMlUyODB6IN88US=> M3LTVXNCVkeHUh?=
NEC8 NGfGSHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rmdmlEPTB;MD63NlEyOyEQvF2= MoGwV2FPT0WU
SW756 NYfnbm42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPV[HAyUUN3ME2wMlk6QDR4IN88US=> Mmj2V2FPT0WU
A2780 M{XSc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTFwMEGxOFYh|ryP Mkm4V2FPT0WU
NB14 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTFwMEG4NFEh|ryP MnrLV2FPT0WU
H4 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXwTWM2OD1zLkC2OFIzKM7:TR?= NH\n[FBUSU6JRWK=
SK-OV-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nhemlEPTB;MT6wOlY{OyEQvF2= Mnv1V2FPT0WU
AN3-CA NILPbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXtZXZiUUN3ME2xMlA5Ozh7IN88US=> NUXGSYtMW0GQR1XS
A427 NEHBTFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Dic2lEPTB;MT6xNFM5OSEQvF2= MlPyV2FPT0WU
ES7 M1j1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\zSIVKSzVyPUGuNVE{OzRizszN M1\lbHNCVkeHUh?=
AGS MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;FTWM2OD1zLkGxN|k2KM7:TR?= NUPWV5JZW0GQR1XS
G-402 NIf3fYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\hTWM2OD1zLkG0Olk1KM7:TR?= MYnTRW5ITVJ?
ES5 NGnpN4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELy[|FKSzVyPUGuNVczPDhizszN NX6xfVNPW0GQR1XS
DEL MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTFwMkW0OVch|ryP M1PhXXNCVkeHUh?=
NB10 NVTpWnhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;qSHpvUUN3ME2xMlMzPTV5IN88US=> M2\2[nNCVkeHUh?=
NCI-H1581 M4LzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLXZ3pGUUN3ME2xMlM6ODR{IN88US=> MXnTRW5ITVJ?
D-566MG NULlZmMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETGUIVKSzVyPUGuOFA3QDNizszN M3XHSnNCVkeHUh?=
LXF-289 M2X6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTVTWM2OD1zLkSzPVk3KM7:TR?= NXfmTphjW0GQR1XS
BT-549 NEP3NWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrpO4VXUUN3ME2xMlU3QTB7IN88US=> MmrKV2FPT0WU
NKM-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTFwNkC1OVYh|ryP M1rZcnNCVkeHUh?=
SW780 M{jkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFwNkWxOVgh|ryP MULTRW5ITVJ?
NCI-H292 M2\kRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPTOWplUUN3ME2xMlY3Ozh|IN88US=> NY\ZUGN{W0GQR1XS
HMV-II MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3XbXRrUUN3ME2xMlcxPDh6IN88US=> MoDvV2FPT0WU
ALL-PO MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1SycGlEPTB;MT64NFAyPSEQvF2= NHnWUJBUSU6JRWK=
UACC-257 NYSyWpdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTFwOEKxOlMh|ryP NWrXNnhqW0GQR1XS
PA-1 MlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIqzTJZKSzVyPUGuPFI4OjVizszN NHvRXI1USU6JRWK=
HD-MY-Z NVv3NItJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PkNGlEPTB;MT64OlI5OSEQvF2= NVXo[HVzW0GQR1XS
HSC-4 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFwOUO4N|kh|ryP MUXTRW5ITVJ?
GCT MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DBZmlEPTB;Mj6wNFkyPiEQvF2= MlP4V2FPT0WU
RT-112 MkfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;jS3VPUUN3ME2yMlE{PDJ2IN88US=> MlO3V2FPT0WU
A172 M3HNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljVTWM2OD1{LkGzOlA3KM7:TR?= MkX5V2FPT0WU
HCE-T M2W4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LPZmlEPTB;Mj6yNFU6QCEQvF2= MmDEV2FPT0WU
YH-13 MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXi4VI93UUN3ME2yMlIyPjdzIN88US=> NVm0SJZlW0GQR1XS
DK-MG NXLlN202T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEOzPGpKSzVyPUKuNlM5OzRizszN M1\WfHNCVkeHUh?=
ACN NXLlWWl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXKzU2t{UUN3ME2yMlI{QDd3IN88US=> Mo\6V2FPT0WU
VA-ES-BJ NFXkbYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\6PJo3UUN3ME2yMlI1QTV5IN88US=> NG\1eZZUSU6JRWK=
L-363 M2X1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUW2S282UUN3ME2yMlI5ODZzIN88US=> NUDwNohSW0GQR1XS
HuH-7 NIDwUmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7QTWM2OD1{LkSyNVY2KM7:TR?= Mo\jV2FPT0WU
A4-Fuk M4O5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2SwOWlEPTB;Mj60O|E3QCEQvF2= NF3mcGNUSU6JRWK=
T-24 NGO4[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJwNEiwN|ch|ryP MmTHV2FPT0WU
GOTO MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJwNUOwNVMh|ryP NFfNV4xUSU6JRWK=
MV-4-11 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf3TpdYUUN3ME2yMlU6OTZ7IN88US=> Mm\1V2FPT0WU
DMS-114 Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjGOXh{UUN3ME2yMlY3OzR3IN88US=> MojqV2FPT0WU
MHH-NB-11 NVTOPXBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTJwN{CyPVkh|ryP NGnUVZNUSU6JRWK=
CHP-212 NIXTb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX5U3JKSzVyPUKuPFIxQTFizszN M3[wfnNCVkeHUh?=
DMS-273 M1W5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu0flVDUUN3ME2yMlkxOjB5IN88US=> NIHqNoRUSU6JRWK=
SF295 NHvtcpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPmc3JHUUN3ME2zMlAzPTl5IN88US=> MmPXV2FPT0WU
NCI-H1563 NEnMdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[2[2pKSzVyPUOuNVUxODVizszN M4jQRnNCVkeHUh?=
NCI-H446 MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLwRnpvUUN3ME2zMlIzQDB3IN88US=> M{Xse3NCVkeHUh?=
HCC1806 NYnER5E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGH0dXJKSzVyPUOuNlc3PTdizszN NYjHVpVMW0GQR1XS
SF126 NV;MSYlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\nTWM2OD1|LkOwNFE4KM7:TR?= NWjlWFU3W0GQR1XS
SW982 NUm2d|Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTNwM{O4O|Uh|ryP MlPKV2FPT0WU
ES8 MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV2zbmdsUUN3ME2zMlM1QTl7IN88US=> NV35T4FJW0GQR1XS
SCC-4 NHG4RWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1T4NGlEPTB;Mz61NFM6PiEQvF2= NX3hWHlLW0GQR1XS
RPMI-8226 MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrsTWM2OD1|Lk[yOlE3KM7:TR?= MVnTRW5ITVJ?
EW-11 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTNwNkOwNlIh|ryP NEWzfJhUSU6JRWK=
COR-L105 NF:3cG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4i1[GlEPTB;Mz62N|M{PCEQvF2= M1HOSXNCVkeHUh?=
ES1 NH\MZ5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTwfnNKSzVyPUOuPFMxQTRizszN NUfRWWJSW0GQR1XS
KMOE-2 NY\iU2dlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTNwOUG4NFgh|ryP M124cnNCVkeHUh?=
ABC-1 MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2raUmlEPTB;Mz65N|kyOSEQvF2= NHXsWWJUSU6JRWK=
NCI-H526 M3vKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzETWM2OD1|Lkm5NVI3KM7:TR?= MWfTRW5ITVJ?
HCC1395 MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTNwOUm0PFQh|ryP NUjjS|V[W0GQR1XS
DU-145 NEOx[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfy[nExUUN3ME20MlEzQDJ3IN88US=> NV;GZ2JjW0GQR1XS
JEG-3 NVKwSWtLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrIdpNbUUN3ME20MlE2QTF4IN88US=> M3HnbnNCVkeHUh?=
HCC1187 NH\lXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDVTWM2OD12LkKxOVk4KM7:TR?= NVPU[pJxW0GQR1XS
LC-2-ad NX;wNGY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjRTWM2OD12LkKyNVc4KM7:TR?= NGDLV2pUSU6JRWK=
ONS-76 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPrOGZpUUN3ME20MlI1OTl{IN88US=> NXO2dY5bW0GQR1XS
CAL-27 NHy1Sm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTRwMkSzOFQh|ryP M3rTNHNCVkeHUh?=
8-MG-BA MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvwO|VTUUN3ME20MlI3PjV6IN88US=> MVTTRW5ITVJ?
HGC-27 NYXyUJRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTRwMkm2OkDPxE1? MmLFV2FPT0WU
Hs-578-T MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[1WFhKSzVyPUSuN|E1PjhizszN NHLPSWFUSU6JRWK=
EW-1 M{K1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jBXGlEPTB;ND61N|AyPCEQvF2= NXf5R|lWW0GQR1XS
SW1573 M2KwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Ox[GlEPTB;ND61OVE3OyEQvF2= MlrCV2FPT0WU
SNU-423 Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHr6[ZpKSzVyPUSuOlA4QSEQvF2= M1nCbHNCVkeHUh?=
HOS NEHYUXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vlfGlEPTB;ND62PVc4KM7:TR?= MUXTRW5ITVJ?
LB1047-RCC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUmwbpBLUUN3ME20MlgyPDF6IN88US=> NFnjWZZUSU6JRWK=
ChaGo-K-1 MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXWXpZKSzVyPUSuPFkxPDhizszN MmPOV2FPT0WU
A3-KAW NYrJSJdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTRwOUezOVIh|ryP Mm\XV2FPT0WU
CAS-1 NVXDZ2tHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\PTWM2OD12Lkm5PVA5KM7:TR?= MVzTRW5ITVJ?
NBsusSR NUXBOo5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXCcZpyUUN3ME21MlA{PTF2IN88US=> NIX5ZZpUSU6JRWK=
KM12 NGTkPGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTVwMkm4Nlch|ryP MnTMV2FPT0WU
NCI-H1155 NEe2bXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDMOGZFUUN3ME21MlM5OTh3IN88US=> NXjqOlNWW0GQR1XS
EFM-19 NYSxT3pwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;PTWM2OD13LkSxO|M4KM7:TR?= NFXrSG1USU6JRWK=
D-392MG MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3qwS2lEPTB;NT61O|g1QSEQvF2= NITpOpVUSU6JRWK=
JVM-3 MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkS4TWM2OD13LkeyN|I2KM7:TR?= NXi3XZpiW0GQR1XS
EW-16 M1exXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3veI5qUUN3ME21Mlc2PTh|IN88US=> NX;xe3F7W0GQR1XS
KARPAS-45 NITK[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTVwOESzNlUh|ryP NHToe5VUSU6JRWK=
NCI-H28 Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDHXGZkUUN3ME21Mlg4QTF6IN88US=> Mm\RV2FPT0WU
COLO-829 NWS1c|JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPRZZFKSzVyPUWuPVE2ODRizszN MmTJV2FPT0WU
KM-H2 NXrEV4dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3LTWM2OD13LkmyN|k2KM7:TR?= M37Z[3NCVkeHUh?=
NCI-H82 M3vDVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13nUGlEPTB;NT65Nlc4OSEQvF2= NWroR5c5W0GQR1XS
OAW-42 NVTqRW46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XvPGlEPTB;NT65PFgzOSEQvF2= MYnTRW5ITVJ?
A704 Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmiyTWM2OD14LkGwOVc1KM7:TR?= M{K5THNCVkeHUh?=
NCI-H1048 MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\NT4xKSzVyPU[uNVA2QTlizszN M4\CRnNCVkeHUh?=
LOXIMVI MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYD4UmNzUUN3ME22MlEyOjR6IN88US=> MVvTRW5ITVJ?
MKN45 NGjySZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDlNnVOUUN3ME22MlI3ODF4IN88US=> M1\pdnNCVkeHUh?=
D-502MG MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG0TWM2OD14LkK4PFU4KM7:TR?= Mnz6V2FPT0WU
HUTU-80 NX3BTWNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTQTWM2OD14LkSxOlg5KM7:TR?= M37lb3NCVkeHUh?=
S-117 NV\mOJhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PkSmlEPTB;Nj61NFI3PyEQvF2= NF3YNGJUSU6JRWK=
HCC1569 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUL6c|FMUUN3ME22MlU{PzN5IN88US=> MmrWV2FPT0WU
J-RT3-T3-5 NWOx[WdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjIW41KSzVyPU[uOVQ2PzJizszN NFLGU4VUSU6JRWK=
OC-314 NVv4PXlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jEUGlEPTB;Nj65NVE2QSEQvF2= M2DJV3NCVkeHUh?=
SNU-449 NWDlTHlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTdwMEGwO|Ih|ryP NVLiRWNEW0GQR1XS
NCI-H720 NUjFRot6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTdwMUmzOFUh|ryP NGXZd|NUSU6JRWK=
KP-N-YS NXLDeVVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnFTWM2OD15LkKwO|Ih|ryP MknhV2FPT0WU
IGROV-1 M{SzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHe5UphKSzVyPUeuN|I{QDZizszN NG\H[nFUSU6JRWK=
SK-PN-DW MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTdwNEixOUDPxE1? M4PoSHNCVkeHUh?=
HCC1419 Mmj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTdwNUOg{txO NY\1fpZQW0GQR1XS
HAL-01 NGTWO|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHQeYxKSzVyPUeuOlA3PDRizszN M3y1ZXNCVkeHUh?=
HCC2998 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHEUHh[UUN3ME23MlYxPzR|IN88US=> MYTTRW5ITVJ?
SK-N-FI NH61coVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnDUnVKSzVyPUeuOlMxOzNizszN M3jXV3NCVkeHUh?=
GI-ME-N NHLSRmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\ITWM2OD15Lk[0PVM1KM7:TR?= MnTLV2FPT0WU
SW1088 NHPpOYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELJ[|RKSzVyPUeuOlU5OjZizszN NGXoZWtUSU6JRWK=
IA-LM MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrWOY17UUN3ME23MlY5PjF|IN88US=> NXzZXlVTW0GQR1XS
SK-NEP-1 NWe0ZYh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\NV2lEPTB;Nz62PVYyKM7:TR?= NW\ROWVYW0GQR1XS
MDA-MB-415 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn70TWM2OD15Lki5NVg3KM7:TR?= NIL5ZWhUSU6JRWK=
COLO-800 NEnwW49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[0TWM2OD15Lkm0OFkzKM7:TR?= MoW2V2FPT0WU
NCI-H2228 M4Ti[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTz[ZZKSzVyPUiuNVU4QDNizszN MVnTRW5ITVJ?
D-423MG MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn4VYlKSzVyPUiuNlE4OiEQvF2= M{j3XXNCVkeHUh?=
TE-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIe1RVJKSzVyPUiuOFQ{OTZizszN M4qzdHNCVkeHUh?=
NOS-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq5NZBmUUN3ME24MlUyPTN2IN88US=> M3LkN3NCVkeHUh?=
8505C NGDxToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvRXXpKSzVyPUiuOlQ5OjRizszN MlG4V2FPT0WU
HEC-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3TOVdKSzVyPUiuO|g1OzlizszN NF\nPWhUSU6JRWK=
TE-11 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Ln[GlEPTB;OD65PVU2OSEQvF2= Moe3V2FPT0WU
CTB-1 NEf6NG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO4cIp5UUN3ME25MlAyPDN|IN88US=> NY\lVnFiW0GQR1XS
TGBC11TKB MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXKd|BLUUN3ME25MlAzOjRzIN88US=> MnjyV2FPT0WU
NB17 M1q3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTlwMUi4O{DPxE1? NULtRnVqW0GQR1XS
Becker NYT0UolDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\FTWM2OD17LkSxPVQ1KM7:TR?= MnXFV2FPT0WU
SN12C M1\TN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnselJKSzVyPUmuOFUzOzRizszN M{nFN3NCVkeHUh?=
COLO-320-HSR Ml\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTlwNkCyN|ch|ryP MkjRV2FPT0WU
D-283MED MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn6UHZKSzVyPUmuOlMxPzJizszN M3frN3NCVkeHUh?=
D-263MG NULIRVhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVG5XYs4UUN3ME25Mlg{Ozh2IN88US=> MkfvV2FPT0WU
MEL-JUSO NGizU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTlwOUCxNlch|ryP NXvhem0yW0GQR1XS
T98G NYq5NFB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTLTWM2OD17LkmwNlA{KM7:TR?= MnPNV2FPT0WU
HLE MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETBb4VKSzVyPUmuPVA6ODlizszN M1mxNnNCVkeHUh?=
Ca9-22 NHrLXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fISmlEPTB;MUCuNFY3PSEQvF2= M4O3UXNCVkeHUh?=
OS-RC-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H5eWlEPTB;MUCuNVA1PSEQvF2= MnzhV2FPT0WU
T47D M13Sfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\FTWM2OD1zMD6xOVUh|ryP M2HQVHNCVkeHUh?=
GI-1 M4LQXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFyLkO1N|Mh|ryP MV;TRW5ITVJ?
NUGC-3 M{niWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFyLkS0NFIh|ryP MoS4V2FPT0WU
MDA-MB-361 NH\kXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvUTWM2OD1zMD60OFMzKM7:TR?= NGHScmpUSU6JRWK=
SCC-15 NYezNlBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHsTWM2OD1zMD60O|E5KM7:TR?= NVnpNJZvW0GQR1XS
KS-1 NWP5fGh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjO[GdKSzVyPUGwMlY{ODFizszN MkfmV2FPT0WU
CAL-12T MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf0TWM2OD1zMD62N|YyKM7:TR?= NV3abFh2W0GQR1XS
OVCAR-4 M{W2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\yZlRuUUN3ME2xNE44ODZ6IN88US=> NW\LUoY2W0GQR1XS
HuP-T4 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HyTGlEPTB;MUGuNFMzQCEQvF2= NXrWOmExW0GQR1XS
NCI-H358 NWDENVJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGGwbWRKSzVyPUGxMlI3PTdizszN Ml7tV2FPT0WU
HO-1-N-1 M2L3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\x[GlEPTB;MUGuN|M6QCEQvF2= MkDvV2FPT0WU
NH-12 Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFzLkWzO|gh|ryP NXzp[3hbW0GQR1XS
MOLT-4 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\3b29KSzVyPUGxMlU6QDVizszN M{j6fnNCVkeHUh?=
K-562 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFzLkeyOFgh|ryP MXnTRW5ITVJ?
ES6 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTFzLki1PFEh|ryP NELid2tUSU6JRWK=
RO82-W-1 MoXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLOSJZKSzVyPUGxMlkxPjRizszN NF;6UZBUSU6JRWK=
Ramos-2G6-4C10 M1nIcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTFzLkmzNkDPxE1? MUnTRW5ITVJ?
23132-87 NFPzZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4D4e2lEPTB;MUKuNFgzOSEQvF2= NFqxbo5USU6JRWK=
A549 M1ntVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTF{LkOyPFUh|ryP MnrYV2FPT0WU
NCI-H23 M2fOdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTJe41jUUN3ME2xNk42ODJ4IN88US=> NF3MbVBUSU6JRWK=
H9 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[5TWM2OD1zMj61OVc4KM7:TR?= MlTSV2FPT0WU
LB771-HNC M2TQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTF{Lke2OUDPxE1? M3e1dnNCVkeHUh?=
QIMR-WIL NIi4eohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Lud2lEPTB;MUKuPFI2QCEQvF2= NEjhUWVUSU6JRWK=
HSC-3 NIjSWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\PRmlEPTB;MUKuPVI4PiEQvF2= MlX0V2FPT0WU
PFSK-1 Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTF{Lkm1NFch|ryP NGXM[WdUSU6JRWK=
ETK-1 M{naZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWH4UVc5UUN3ME2xN{4xPzd7IN88US=> NFLaNm9USU6JRWK=
SW1710 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\OeJZKSzVyPUGzMlM3PDFizszN MlHPV2FPT0WU
COLO-684 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHybpBKSzVyPUGzMlQ2PDFizszN MXjTRW5ITVJ?
RPMI-7951 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVq4OY1bUUN3ME2xN{42OTN4IN88US=> MVvTRW5ITVJ?
A101D MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\IbGlEPTB;MUOuOVM1QSEQvF2= M3exZ3NCVkeHUh?=
KE-37 NFPTbVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rDeGlEPTB;MUOuOVg5PyEQvF2= MXHTRW5ITVJ?
SiHa NFvzZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvnVWJKSzVyPUGzMlg{PDZizszN NXzPVodjW0GQR1XS
NCI-H226 NFHofoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlq2TWM2OD1zMz64PFA5KM7:TR?= M{PZWXNCVkeHUh?=
DB NX:2PFl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF|Lkm5Nlgh|ryP MkDMV2FPT0WU
HT-1197 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnBTWM2OD1zND6wPFA6KM7:TR?= MWDTRW5ITVJ?
SBC-5 NHHFeYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH0TWM2OD1zND6xN|YzKM7:TR?= MorUV2FPT0WU
VMRC-RCZ MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrKS2hKSzVyPUG0MlU4PzRizszN NXHxXFZZW0GQR1XS
697 M1f5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF2Lk[yO{DPxE1? M2rKeXNCVkeHUh?=
OMC-1 NVvyd2VLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moq3TWM2OD1zND63PFg5KM7:TR?= MmT0V2FPT0WU
SKG-IIIa MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDsTWM2OD1zND64NFAyKM7:TR?= NIG2dpdUSU6JRWK=
DOK MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;lTFZIUUN3ME2xOE46QTN|IN88US=> MojjV2FPT0WU
NCI-H2029 M1K1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljrTWM2OD1zNT6zOlAzKM7:TR?= MVPTRW5ITVJ?
NCI-H2009 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\YdmxvUUN3ME2xOU42ODl3IN88US=> NEftcllUSU6JRWK=
LK-2 M1;WNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHoN2NWUUN3ME2xOU43PDR7IN88US=> Mk\RV2FPT0WU
NCI-H661 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTF3LkmwO|Uh|ryP MnXUV2FPT0WU
GT3TKB NGHKRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPoSlRWUUN3ME2xOk4xPjd4IN88US=> NYPWRlA3W0GQR1XS
GP5d M{XEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHu1Z5lKSzVyPUG2MlM1OiEQvF2= M{TPXHNCVkeHUh?=
SK-MEL-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvaTJRKSzVyPUG2MlQ1QDVizszN MYXTRW5ITVJ?
SK-UT-1 NG\kOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HuN2lEPTB;MU[uOVY2KM7:TR?= MYTTRW5ITVJ?
NB7 NIDaPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPvdFVKSzVyPUG2MlY6PzFizszN NVjhOmRlW0GQR1XS
NCI-H460 Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nETWlEPTB;MU[uO|MzPiEQvF2= M{nZRnNCVkeHUh?=
8305C Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\mOnpKSzVyPUG2Mlc5PzdizszN M1K3cXNCVkeHUh?=
CaR-1 M{nYe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfkSFVKSzVyPUG2MlgyOTFizszN NUe0V2trW0GQR1XS
D-247MG NV;NR5lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID0OnFKSzVyPUG2Mlg3OjVizszN NIj5OFdUSU6JRWK=
LoVo NFW0cIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITDNo5KSzVyPUG2Mlk1QDhizszN NX\mclVRW0GQR1XS
NCI-H2405 M{D5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHlNFE3UUN3ME2xO{4yQTB6IN88US=> NVXUNpJZW0GQR1XS
AU565 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYm3R21JUUN3ME2xO{4zOjVizszN NITrZWlUSU6JRWK=
OCI-AML2 NHHOO2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MornTWM2OD1zNz61N|E4KM7:TR?= NXToVJhuW0GQR1XS
22RV1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\5XFNKSzVyPUG3MlU5QDRizszN MWXTRW5ITVJ?
HT-144 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTF5Lk[1PVgh|ryP MX7TRW5ITVJ?
HuO9 NVTlTVRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXXTHVKSzVyPUG3MlcxOzFizszN MWTTRW5ITVJ?
Daoy MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmP4TWM2OD1zNz63NVg1KM7:TR?= NHW3OGpUSU6JRWK=
SJRH30 M2LCU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXBTWM2OD1zNz64OFg6KM7:TR?= MVHTRW5ITVJ?
CHL-1 NULiV5hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXZS3FKSzVyPUG3MlkzPDlizszN M2ruOnNCVkeHUh?=
J82 M4SzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TkU2lEPTB;MUeuPVY{PSEQvF2= MWnTRW5ITVJ?
COR-L23 MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF6LkCwNVEh|ryP Moq4V2FPT0WU
SNU-C2B MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHWOFlKSzVyPUG4MlIzPzZizszN M2fi[HNCVkeHUh?=
NCI-H1770 NVLF[pJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXP1WoUxUUN3ME2xPE41PjF3IN88US=> MojkV2FPT0WU
MHH-PREB-1 NE\wSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF6LkW2PVch|ryP NGjBRlZUSU6JRWK=
ES3 NUXaVJh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfPRWtKSzVyPUG4MlU5QDNizszN MmruV2FPT0WU
MDA-MB-231 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTYTWM2OD1zOD62OVAzKM7:TR?= MnvCV2FPT0WU
MN-60 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTF7LkC1PVIh|ryP NWqwcmw3W0GQR1XS
EPLC-272H NVG4OpFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX3TWM2OD1zOT6zO|A5KM7:TR?= NHr4R5VUSU6JRWK=
SW948 NEjr[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW0TWM2OD1zOT6zPVM1KM7:TR?= M{f5OHNCVkeHUh?=
MOLT-13 M2PicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPPeJRPUUN3ME2xPU41PTR4IN88US=> M1XRTnNCVkeHUh?=
HL-60 M2PnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3z0fmlEPTB;MkCuNlE1OSEQvF2= M2nmdHNCVkeHUh?=
CP50-MEL-B MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTJyLkS3OFgh|ryP NXPNdmMzW0GQR1XS
NTERA-S-cl-D1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\UOldmUUN3ME2yNE41QTd6IN88US=> NYjid5hTW0GQR1XS
KINGS-1 M2jicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkD5TWM2OD1{MD63PVY4KM7:TR?= NHTINYxUSU6JRWK=
DOHH-2 NGH4RoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfJWZNKSzVyPUKwMlkxPiEQvF2= NIPtSJBUSU6JRWK=
BB65-RCC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\rcml1UUN3ME2yNE46Ojh3IN88US=> MlLSV2FPT0WU
NB12 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHP3dW9KSzVyPUKxMlA{QTRizszN M3GyRXNCVkeHUh?=
KY821 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7pOplKSzVyPUKxMlU5OiEQvF2= NIm2[ZhUSU6JRWK=
PSN1 MoHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f6TGlEPTB;MkGuOlQ2OyEQvF2= MoT6V2FPT0WU
EGI-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnyUGRnUUN3ME2yNU44PDV2IN88US=> NFO2NHdUSU6JRWK=
CTV-1 M4jhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zpd2lEPTB;MkKuN|A{OSEQvF2= MoTOV2FPT0WU
TI-73 M2X4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP1VFhpUUN3ME2yNk4{PDl6IN88US=> M1rUbHNCVkeHUh?=
LCLC-103H MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULEd4w6UUN3ME2yNk41PzV{IN88US=> MmX4V2FPT0WU
D-542MG MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDETWM2OD1{Mj61OVU5KM7:TR?= MVHTRW5ITVJ?
ATN-1 MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\ZS|hJUUN3ME2yNk43PDN7IN88US=> NI\Ob3BUSU6JRWK=
SK-MEL-1 Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O2Z2lEPTB;MkKuPFM3QCEQvF2= M{PoSHNCVkeHUh?=
HDLM-2 Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPpOXdKSzVyPUKzMlE1PzhizszN NGr1[GxUSU6JRWK=
UM-UC-3 M2\SUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJ|LkG5OFQh|ryP MoXHV2FPT0WU
NCI-H1573 NHf1fmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjVTWM2OD1{Mz60OlgyKM7:TR?= NHGyS3VUSU6JRWK=
NCI-H520 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;jSmlEPTB;MkOuOFk1QCEQvF2= MlX3V2FPT0WU
ESS-1 NIjNc2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPwTWM2OD1{Mz64NFU6KM7:TR?= NX;JVHFkW0GQR1XS
COR-L88 NX7KOIJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHYWZlKSzVyPUKzMlk1PzVizszN MojqV2FPT0WU
TGBC24TKB M2nKcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3n2eGlEPTB;MkSuNFMyOiEQvF2= M3uyVXNCVkeHUh?=
HCC1937 NHHmenRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITaRpRKSzVyPUK0MlEh|ryP M1O4SHNCVkeHUh?=
RS4-11 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3nUpJKSzVyPUK0MlE1OiEQvF2= M{PKeXNCVkeHUh?=
HCC38 M4LDPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTQN21NUUN3ME2yOE4zOzl2IN88US=> Mmi3V2FPT0WU
RPMI-2650 M3HjfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPOSppKSzVyPUK0MlYyPjJizszN M4nOcnNCVkeHUh?=
P12-ICHIKAWA Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DINmlEPTB;MkSuOlI2QCEQvF2= MkTGV2FPT0WU
YAPC MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4mwXmlEPTB;MkSuPFIyPCEQvF2= MYLTRW5ITVJ?
NB13 M1rNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn64TWM2OD1{NT6yOlEyKM7:TR?= MWTTRW5ITVJ?
SK-N-AS NITQdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3S1OGlEPTB;MkWuPFU5PCEQvF2= M{PKNXNCVkeHUh?=
SK-N-DZ NYTZdI5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HhVmlEPTB;Mk[uNFQ6KM7:TR?= M2HYT3NCVkeHUh?=
LS-411N M2mxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f1UmlEPTB;Mk[uNlA{QCEQvF2= NEXsfpJUSU6JRWK=
NCI-H810 NYPicXRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvRTWM2OD1{Nj6zNVEzKM7:TR?= NH;qeodUSU6JRWK=
NCI-SNU-1 NGTzNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTJ4LkW0OVQh|ryP M2fXO3NCVkeHUh?=
HH NE\qTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL6WFhRUUN3ME2yOk42PTJ7IN88US=> NFTxO|ZUSU6JRWK=
U-2-OS MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;XOIlDUUN3ME2yOk44Ozh{IN88US=> MmT6V2FPT0WU
SF539 M4e3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjidG1XUUN3ME2yOk45ODF6IN88US=> NGTFNZJUSU6JRWK=
NCI-H2052 NHPNPJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vBZmlEPTB;MkeuNFg3KM7:TR?= Ml3nV2FPT0WU
A673 NFfBN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L6d2lEPTB;MkeuNlExOiEQvF2= NWDWXnZpW0GQR1XS
WM-115 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrJVmVuUUN3ME2yO{44PzZ5IN88US=> Ml7ZV2FPT0WU
SW48 NGLkenlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJ5LkiwNFUh|ryP NXj0e4RyW0GQR1XS
NOMO-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjVTWM2OD1{Nz64OVMzKM7:TR?= NXG1dJFIW0GQR1XS
PC-3 NUOzflJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTJ5Lki5OFEh|ryP NIfNdoVUSU6JRWK=
UMC-11 NVv4c|RlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;ycGlEPTB;MkeuPVM1OyEQvF2= NFrCdJRUSU6JRWK=
U-118-MG MnXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjmUZhGUUN3ME2yPE4xOTJ|IN88US=> NYHmd4dyW0GQR1XS
NCI-H2452 NE\zOWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJ6LkC4NlIh|ryP NXv1bVlsW0GQR1XS
CAMA-1 MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\PTWM2OD1{OD64OVY1KM7:TR?= MmHOV2FPT0WU
MC-IXC M37VSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HOdmlEPTB;MkmuNlM3PiEQvF2= NUS2T3FVW0GQR1XS
ES4 Ml3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXJdmpoUUN3ME2yPU4{OTd{IN88US=> M4HlbnNCVkeHUh?=
BHT-101 NEKzVJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nsZmlEPTB;MkmuN|IyKM7:TR?= M4TUW3NCVkeHUh?=
KP-4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\xdmlEPTB;MkmuOVE3KM7:TR?= NFG5W|NUSU6JRWK=
CAL-54 M1e1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe3VmhKSzVyPUK5MlU1PDVizszN M2ezTnNCVkeHUh?=
5637 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fEWGlEPTB;MkmuOlQzOSEQvF2= M4jIcnNCVkeHUh?=
MOLT-16 NUmxZWJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXZeWxZUUN3ME2yPU44OjZ7IN88US=> NF7SfJZUSU6JRWK=
Ca-Ski MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ThbGlEPTB;MkmuPVQ3KM7:TR?= M3HYc3NCVkeHUh?=
AsPC-1 M2DUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1X4Z2lEPTB;M{CuNFIyOiEQvF2= Mn\CV2FPT0WU
MSTO-211H M{DobWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTNyLkG1JO69VQ>? M4OyTHNCVkeHUh?=
L-428 M2WzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHOxWZBKSzVyPUOwMlQxPSEQvF2= NFz5So5USU6JRWK=
SW1463 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnMOHNKSzVyPUOwMlU{QDNizszN MoXqV2FPT0WU
NCI-H1648 NXLmbIg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPNTWM2OD1|MD61OVc1KM7:TR?= NFTM[JZUSU6JRWK=
CAKI-1 MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHpR2pKUUN3ME2zNE44PzB{IN88US=> NFrXe4VUSU6JRWK=
YKG-1 NYrDXWdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTNzLkCyOlMh|ryP M2D5O3NCVkeHUh?=
A2058 NFnMfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4i4[WlEPTB;M{GuNVE3PCEQvF2= MY\TRW5ITVJ?
A375 M2Xxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7hTWM2OD1|MT6xOlk3KM7:TR?= MVvTRW5ITVJ?
SNB75 M{HHXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nnXmlEPTB;M{GuNlQ{PSEQvF2= Ml;NV2FPT0WU
SK-HEP-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S2ZWlEPTB;M{GuOFI4OSEQvF2= NVLLNmNIW0GQR1XS
ME-180 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjZTWZQUUN3ME2zNU43PTR{IN88US=> Mo\4V2FPT0WU
NCI-H209 M3zCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjIRolmUUN3ME2zNU45OjR5IN88US=> MnX4V2FPT0WU
HC-1 NXzKeXZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7JSVdKSzVyPUOyMlE1PDZizszN MmLoV2FPT0WU
LB373-MEL-D NWe5UXBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn23TWM2OD1|Mj6xPVcyKM7:TR?= MnfoV2FPT0WU
SNU-387 M3TXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTN{LkOxPVEh|ryP NIfURWlUSU6JRWK=
C32 M2ixfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X0W2lEPTB;M{KuN|M2OyEQvF2= M4HaS3NCVkeHUh?=
EW-13 NH;EOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILB[oVKSzVyPUOyMlk1ODhizszN MXHTRW5ITVJ?
BFTC-905 MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTN|LkWxN|Yh|ryP MVvTRW5ITVJ?
NCI-H1299 MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTN|LkW2NlEh|ryP MXPTRW5ITVJ?
LU-135 M1e4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37SSWlEPTB;M{OuPFAyKM7:TR?= M33UcXNCVkeHUh?=
NCI-H2122 NVKze4p4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPKTWM2OD1|Mz65PVY3KM7:TR?= NH;pOWxUSU6JRWK=
SK-LMS-1 NVjpNmh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvUTWM2OD1|ND60NVA4KM7:TR?= NWXoXlJwW0GQR1XS
LNCaP-Clone-FGC MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTN2Lki1NVUh|ryP NGPF[Y5USU6JRWK=
NCI-H1092 MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq4Wlk3UUN3ME2zOU4zPzR5IN88US=> NH6yUmxUSU6JRWK=
MS-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHr4RVZKSzVyPUO1MlMxOzhizszN M3Lzd3NCVkeHUh?=
KYSE-510 M2LGUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPS[GJKSzVyPUO1MlUxPDJizszN NUnMXWN5W0GQR1XS
NCI-H1793 MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfmeJFYUUN3ME2zOU43PTR3IN88US=> NVX2UG1zW0GQR1XS
MIA-PaCa-2 M{TNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;1UWlEPTB;M{[uNFQ6PiEQvF2= M{ftNXNCVkeHUh?=
EW-22 NFXVOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\Gc5hoUUN3ME2zOk41ODd{IN88US=> NYLvZndJW0GQR1XS
IGR-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjnbW1CUUN3ME2zOk45OTh2IN88US=> MlnRV2FPT0WU
HT-1080 MoG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS1TWM2OD1|Nz6xNlUh|ryP MXzTRW5ITVJ?
M14 NGW3TG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XjUGlEPTB;M{euNVY1OiEQvF2= MkX5V2FPT0WU
786-0 NGT1bHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LyOGlEPTB;M{euNlc6PCEQvF2= MYTTRW5ITVJ?
MZ2-MEL NFfh[INIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{K3ZWlEPTB;M{euOFUxOSEQvF2= MlO2V2FPT0WU
NCI-H510A MmnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTN5Lkm0NVIh|ryP NI\1dGhUSU6JRWK=
LAN-6 NYHHNWN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PwUGlEPTB;M{euPVU5OiEQvF2= MU\TRW5ITVJ?
SW620 M1yyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTN6LkS5O|Qh|ryP NInqVpRUSU6JRWK=
LB2241-RCC NEDWVnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTN7LkiyNFUh|ryP Mlr5V2FPT0WU
Detroit562 NHXoSJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVn2c4sxUUN3ME20NE4yOjZ6IN88US=> NILme45USU6JRWK=
HN MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDGdXB3UUN3ME20NE4yPzh{IN88US=> Ml7WV2FPT0WU
HCT-15 NEjPS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[1eWlEPTB;NECuOVkxPyEQvF2= MVHTRW5ITVJ?
C2BBe1 Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTRyLkmxOVch|ryP M1TDSnNCVkeHUh?=
A498 NGfuXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTRzLkOwNVUh|ryP NVjOW|V7W0GQR1XS
SK-MEL-24 M2q2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvV[JBHUUN3ME20NU41PzJ3IN88US=> MYnTRW5ITVJ?
OVCAR-5 NHv2VYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\yTWM2OD12MT63O|Y4KM7:TR?= NULsdVV2W0GQR1XS
NCI-H1792 NFSzSHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXnNohVUUN3ME20NU46QDJzIN88US=> MnPwV2FPT0WU
KOSC-2 MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\RTFlKSzVyPUSyMlI3QTlizszN MXvTRW5ITVJ?
Mo-T NHT4WmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPDZ4RKSzVyPUSyMlg6PThizszN NWD0UGFtW0GQR1XS
CFPAC-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTR|LkS5OFQh|ryP M4DI[3NCVkeHUh?=
CAL-51 NU\pbFIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTR|LkW2NFUh|ryP NXnjUGRVW0GQR1XS
RH-18 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml6xTWM2OD12Mz64NFUh|ryP MoDIV2FPT0WU
EC-GI-10 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTR|LkizOFch|ryP NX7KR5o6W0GQR1XS
HSC-2 NEG4Nm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvlfZp[UUN3ME20OE4xODlizszN MlvWV2FPT0WU
ML-2 MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjGOmdKSzVyPUS1MlI3OjFizszN NIT5XGJUSU6JRWK=
KNS-81-FD NInWd2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\x[FVlUUN3ME20OU44OzZ3IN88US=> MlrhV2FPT0WU
NB6 NUWxd|ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XzS2lEPTB;NE[uNVEyKM7:TR?= M3THcHNCVkeHUh?=
MCF7 NETUWHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfOUG13UUN3ME20Ok42PTN|IN88US=> MnzRV2FPT0WU
P30-OHK NH7LO3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfWTWM2OD12Nj64NVE4KM7:TR?= MX;TRW5ITVJ?
BPH-1 M4rYXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELLVGtKSzVyPUS2Mlk5ODVizszN MnvzV2FPT0WU
U251 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTR4Lkm5OEDPxE1? MVPTRW5ITVJ?
MKN1 M2jpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe5TWM2OD12Nz61NVM4KM7:TR?= MXXTRW5ITVJ?
A431 NFTPcVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nBN2lEPTB;NEeuPFM{QCEQvF2= MW\TRW5ITVJ?
C8166 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfvTWM2OD12OT6yNFM6KM7:TR?= MXPTRW5ITVJ?
HEL NHr3V2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV32THk5UUN3ME20PU41ODZ2IN88US=> MnXEV2FPT0WU
RMG-I NVOxOYFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPqNFhKSzVyPUS5MlQ1PDRizszN MnrPV2FPT0WU
CAL-72 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTR7Lk[wO|Uh|ryP M4P5THNCVkeHUh?=
SW962 M3fTOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHqwPHdKSzVyPUS5Mlk{OzJizszN MUnTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-c-kit / c-kit / p-AKT / AKT / p-ERK / ERK / p-STAT3 / STAT3 / p-STAT5 / STAT5 / p-S6K / S6K / p-S6 / S6; 

PubMed: 31205508     


Immunoblotting analysis of indicated proteins in c-KIT mediated signaling pathways of GIST-T1, GIST-882, GIST-48B, and GIST-5R cell lines.

PARP / cleaved PARP / caspase-3 / cleaved caspase-3; 

PubMed: 31205508     


Immunoblotting analysis of apoptosis-related proteins after axitinib treatment in human GIST cell lines. Imatinib and sunitinib were used as positive controls.

31205508
Immunofluorescence
alpha-tubulin; 

PubMed: 26474283     


Representative images of RCC cells treated as above described, and then immunostained with anti-α-tubulin antibody. Bar: 50 μM

26474283
Growth inhibition assay
Cell viability ; 

PubMed: 26474283     


A. A-498 and Caki-2 RCC cell lines were cultured up to 96 h with different doses of axitinib. Cell viability was determined by MTT assay. Data shown are expressed as mean ± SD of three separate experiments; *p < 0.01 vs vehicle-treated cells. B. RCC cell 䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕€

26474283
In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay:

[1]

+ Expand

Cellular receptor kinase phosphorylation assay:

Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research:

[2]

+ Expand
  • Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
  • Concentrations: 1 nM - 10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
  • Formulation: 0.5% carboxymethylcellulose (CMC)
  • Dosages: 10, 30 or 100 mg/kg
  • Administration: Oral daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL warmed (90.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
0.5% CMC
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage powder
in solvent
Synonyms AG 013736

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03826589 Not yet recruiting Cervical Cancer The University of Hong Kong June 1 2019 Not Applicable
NCT03826589 Not yet recruiting Cervical Cancer The University of Hong Kong June 1 2019 Not Applicable
NCT03839498 Recruiting Pheochromocytoma|Paraganglioma Columbia University|Pfizer January 22 2019 Phase 2
NCT03839498 Recruiting Pheochromocytoma|Paraganglioma Columbia University|Pfizer January 22 2019 Phase 2
NCT03595124 Recruiting Metastatic Renal Cell Carcinoma|Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|TFE3 Gene Translocation|TFEB Gene Translocation National Cancer Institute (NCI) October 9 2018 Phase 2
NCT03595124 Recruiting Metastatic Renal Cell Carcinoma|Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|TFE3 Gene Translocation|TFEB Gene Translocation National Cancer Institute (NCI) October 9 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We would like to store at -80℃ after it dissolved in CMC. Do you have any infomation about the suggested concentration in CMC?

  • Answer:

    Axitinib in 0.5% CMC at up to 30mg/ml is a suspension for oral gavage administration only. We don't suggest customer to freeze down the solution but to make fresh if possible. Customer can store it for 1-2 weeks at 4 degree for continuous use.

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products4

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID